Allogene Therapeutics
132 articles with Allogene Therapeutics
-
Allogene Therapeutics Reports Second Quarter 2022 Financial Results
8/9/2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter ended June 30, 2022.
-
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
8/3/2022
Allogene Therapeutics, Inc. today announced that management plans to participate in three upcoming investor conferences.
-
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET
7/27/2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report second quarter 2022 financial results on Tuesday, August 9, 2022, after the close of the market.
-
Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors
7/12/2022
Allogene Therapeutics, Inc. announced the appointment of Stephen L. Mayo, Ph.D., a world renowned expert in computational protein design, to the company’s Board of Directors.
-
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
6/8/2022
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma.
-
Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
5/19/2022
Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.
-
Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal
5/9/2022
Allogene Therapeutics, Inc. announced that the San Francisco Business Times and the Silicon Valley Business Journal ranked Allogene as the highest rated biotechnology company – and 12th company overall – on the 2022 Best Places to Work in the Bay Area list in the large company category.
-
After the market closed on Wednesday, Allogene reported its first-quarter financial results, along with updates to its research programs. The report marked Allogene's fourth anniversary.
-
Allogene Therapeutics Reports First Quarter 2022 Financial Results
5/4/2022
Allogene Therapeutics, Inc. provided a corporate update and reported financial results for the quarter ended March 31, 2022.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer
4/28/2022
Allogene Therapeutics, Inc. today announced the appointment of Susan Lundeen as Chief People Officer effective May 2, 2022.
-
Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022
4/27/2022
Allogene Therapeutics, Inc. today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022 after the close of the market.
-
Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma
4/27/2022
Allogene Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) to ALLO-605, the Company’s next-generation AlloCAR T product candidate targeting BCMA for the treatment of multiple myeloma.
-
The new facility is expected to bolster innovation across all facets of manufacturing to allow the company to fully develop and commercialize cancer treatments for patients in need.
-
The AACR annual meeting concluded on April 13, showcasing hundreds of preclinical to late-stage information from ongoing studies on treatment candidates.
-
Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products
4/14/2022
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced the virtual unveiling of its manufacturing facility, Cell Forge 1, located in Newark, California.
-
Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal
4/13/2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced that new preclinical findings of ALLO-316, an AlloCAR T therapy targeting CD70 for the treatment of renal cell carcinoma (RCC), were presented in a poster session of the 2022 American Association for Cancer Research (AACR) Annual Meeting.
-
Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences
4/12/2022
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced that management plans to participate in seven upcoming investor conferences.
-
Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma
3/23/2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the publication of preclinical study results demonstrating the superior long-term in vitro myeloma-killing activity of allogeneic anti-BCMA CAR T cells from healthy donors compared with anti-BCMA CAR T cells from patients with multiple myeloma.
-
Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
3/10/2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to ALLO-316, the Company’s first AlloCAR T solid tumor clinical candidate for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC).